210 related articles for article (PubMed ID: 18690830)
1. Progress on kinesin spindle protein inhibitors as anti-cancer agents.
Zhang Y; Xu W
Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830
[TBL] [Abstract][Full Text] [Related]
2. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
Nagarajan S; Skoufias DA; Kozielski F; Pae AN
J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
[TBL] [Abstract][Full Text] [Related]
3. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP.
Rickert KW; Schaber M; Torrent M; Neilson LA; Tasber ES; Garbaccio R; Coleman PJ; Harvey D; Zhang Y; Yang Y; Marshall G; Lee L; Walsh ES; Hamilton K; Buser CA
Arch Biochem Biophys; 2008 Jan; 469(2):220-31. PubMed ID: 17999913
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of human KSP by ispinesib.
Lad L; Luo L; Carson JD; Wood KW; Hartman JJ; Copeland RA; Sakowicz R
Biochemistry; 2008 Mar; 47(11):3576-85. PubMed ID: 18290633
[TBL] [Abstract][Full Text] [Related]
5. Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
Sheth PR; Basso A; Duca JS; Lesburg CA; Ogas P; Gray K; Nale L; Mannarino AF; Prongay AJ; Le HV
Biochemistry; 2009 Nov; 48(46):11045-55. PubMed ID: 19824700
[TBL] [Abstract][Full Text] [Related]
6. KSP inhibitors as antimitotic agents.
Pérez-Melero C
Curr Top Med Chem; 2014; 14(20):2286-311. PubMed ID: 25434354
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.
Luo L; Carson JD; Dhanak D; Jackson JR; Huang PS; Lee Y; Sakowicz R; Copeland RA
Biochemistry; 2004 Dec; 43(48):15258-66. PubMed ID: 15568818
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
Kaan HY; Ulaganathan V; Rath O; Prokopcová H; Dallinger D; Kappe CO; Kozielski F
J Med Chem; 2010 Aug; 53(15):5676-83. PubMed ID: 20597485
[TBL] [Abstract][Full Text] [Related]
9. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
Cox CD; Garbaccio RM
Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
[TBL] [Abstract][Full Text] [Related]
10. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
Cox CD; Breslin MJ; Mariano BJ; Coleman PJ; Buser CA; Walsh ES; Hamilton K; Huber HE; Kohl NE; Torrent M; Yan Y; Kuo LC; Hartman GD
Bioorg Med Chem Lett; 2005 Apr; 15(8):2041-5. PubMed ID: 15808464
[TBL] [Abstract][Full Text] [Related]
11. Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.
Song H; Zhou S; Wang R; Li S
ChemMedChem; 2013 Nov; 8(11):1736-49. PubMed ID: 23964020
[TBL] [Abstract][Full Text] [Related]
12. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.
Liu F; Yu LQ; Jiang C; Yang L; Wu WT; You QD
Bioorg Med Chem; 2010 Jun; 18(12):4167-77. PubMed ID: 20537544
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP.
Knight SD; Parrish CA
Curr Top Med Chem; 2008; 8(10):888-904. PubMed ID: 18673173
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
Müller C; Gross D; Sarli V; Gartner M; Giannis A; Bernhardt G; Buschauer A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):157-64. PubMed ID: 16703323
[TBL] [Abstract][Full Text] [Related]
16. Targeting the kinesin spindle protein: basic principles and clinical implications.
Sarli V; Giannis A
Clin Cancer Res; 2008 Dec; 14(23):7583-7. PubMed ID: 19047082
[TBL] [Abstract][Full Text] [Related]
17. Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors.
Matsuno K; Sawada J; Sugimoto M; Ogo N; Asai A
Bioorg Med Chem Lett; 2009 Feb; 19(4):1058-61. PubMed ID: 19167222
[TBL] [Abstract][Full Text] [Related]
18. Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds.
Oishi S; Watanabe T; Sawada J; Asai A; Ohno H; Fujii N
J Med Chem; 2010 Jul; 53(13):5054-8. PubMed ID: 20521839
[TBL] [Abstract][Full Text] [Related]
19. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor.
Liu M; Yu H; Huo L; Liu J; Li M; Zhou J
Biochem Pharmacol; 2008 Jul; 76(2):169-78. PubMed ID: 18539263
[TBL] [Abstract][Full Text] [Related]
20. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
